Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Basic Research

Transcriptional repression of RUNX2 is associated with aggressive clinicopathological outcomes, whereas nuclear location of the protein is related to metastasis in prostate cancer

Prostate Cancer and Prostatic Diseases volume 15, pages 369–373 (2012)Cite this article

Subjects

Abstract

Background:

Runt-related transcription factor 2 (RUNX2) is a transcription factor that is closely related to bone formation, and prostate cancer (CaP) is the most common cancer to metastasize to bone. The present study investigated the expression levels of RUNX2 in human prostate tissue, and the correlation between RUNX2 levels and the clinicopathological characteristics of CaP.

Methods:

A case–control study was conducted including 114 cases of newly diagnosed CaP and 114 age-matched BPH patients as controls. RUNX2 expression was estimated using real-time PCR and immunohistochemical staining.

Results:

The mRNA expression of RUNX2 did not differ between CaP tissues and non-cancer BPH controls (P=0.825). However, RUNX2 expression was significantly decreased in patients with elevated PSA levels (⩾20 ng ml−1), a Gleason score ⩾8 and metastatic disease compared to those with low PSA, low Gleason score and non-metastatic disease (P=0.023, 0.005 and 0.014, respectively). Immunohistochemical analysis showed that 65.2% of the patients with positive RUNX2 nuclear staining had metastatic disease, which was present in only 25.9% of those with negative staining (P=0.010).

Conclusions:

RUNX2 mRNA expression was negatively correlated with CaP aggressiveness. Moreover, the nuclear location of RUNX2 may be a prognostic marker of metastasis in CaP.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. de Bruijn MF, Speck NA . Core-binding factors in hematopoiesis and immune function. Oncogene 2004; 23: 4238–4248.

    Article  CAS  PubMed  Google Scholar 

  2. Fukamachi H, Ito K . Growth regulation of gastric epithelial cells by Runx3. Oncogene 2004; 23: 4330–4335.

    Article  CAS  PubMed  Google Scholar 

  3. Tubert P, Rodriguez M, Ribo M, Benito A, Vilanova M . The nuclear transport capacity of a human-pancreatic ribonuclease variant is critical for its cytotoxicity. Invest New Drugs 2011; 29: 811–817.

    Article  CAS  PubMed  Google Scholar 

  4. Bradford WD, Dolan P . Getting used to it: the adaptive global utility model. J Health Econ 2010; 29: 811–820.

    Article  PubMed  Google Scholar 

  5. Boult C, Counsell SR, Leipzig RM, Berenson RA . The urgency of preparing primary care physicians to care for older people with chronic illnesses. Health Aff (Millwood) 2010; 29: 811–818.

    Article  Google Scholar 

  6. Srivastava MC, Ramani GV, Garcia JP, Griffith BP, Uber PA, Park MH . Veno-venous extracorporeal membrane oxygenation bridging to pharmacotherapy in pulmonary arterial hypertensive crisis. J Heart Lung Transplant 2010; 29: 811–813.

    Article  PubMed  Google Scholar 

  7. Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G . Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 1997; 89: 747–754.

    Article  CAS  PubMed  Google Scholar 

  8. Kobayashi H, Gao Y, Ueta C, Yamaguchi A, Komori T . Multilineage differentiation of Cbfa1-deficient calvarial cells in vitro. Biochem Biophys Res Commun 2000; 273: 630–636.

    Article  CAS  PubMed  Google Scholar 

  9. Stojanovic R, Todorovic Z, Vuckovic S, Nesic Z, Prostran M . Nitric oxide and lung diseases. Med Pregl 2003; 56 (Suppl 1): 13–17.

    PubMed  Google Scholar 

  10. Awiszus F . TMS and threshold hunting. Suppl Clin Neurophysiol 2003; 56: 13–23.

    Article  PubMed  Google Scholar 

  11. Clarke EJ, Allan VJ . Cytokeratin intermediate filament organisation and dynamics in the vegetal cortex of living Xenopus laevis oocytes and eggs. Cell Motil Cytoskeleton 2003; 56: 13–26.

    Article  PubMed  Google Scholar 

  12. Park SK, Sakoda LC, Kang D, Chokkalingam AP, Lee E, Shin HR et al. Rising prostate cancer rates in South Korea. Prostate 2006; 66: 1285–1291.

    Article  PubMed  Google Scholar 

  13. Akech J, Wixted JJ, Bedard K, van der Deen M, Hussain S, Guise TA et al. Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene 2010; 29: 811–821.

    Article  CAS  Google Scholar 

  14. Brubaker KD, Vessella RL, Brown LG, Corey E . Prostate cancer expression of runt-domain transcription factor Runx2, a key regulator of osteoblast differentiation and function. Prostate 2003; 56: 13–22.

    Article  CAS  PubMed  Google Scholar 

  15. Pratap J, Lian JB, Javed A, Barnes GL, van Wijnen AJ, Stein JL et al. Regulatory roles of Runx2 in metastatic tumor and cancer cell interactions with bone. Cancer Metastasis Rev 2006; 25: 589–600.

    Article  CAS  Google Scholar 

  16. Javed A, Barnes GL, Pratap J, Antkowiak T, Gerstenfeld LC, van Wijnen AJ et al. Impaired intranuclear trafficking of Runx2 (AML3/CBFA1) transcription factors in breast cancer cells inhibits osteolysis in vivo. Proc Natl Acad Sci USA 2005; 102: 1454–1459.

    Article  CAS  PubMed  Google Scholar 

  17. Yeung F, Law WK, Yeh CH, Westendorf JJ, Zhang Y, Wang R et al. Regulation of human osteocalcin promoter in hormone-independent human prostate cancer cells. J Biol Chem 2002; 277: 2468–2476.

    Article  CAS  PubMed  Google Scholar 

  18. Chua CW, Chiu YT, Yuen HF, Chan KW, Man K, Wang X et al. Suppression of androgen-independent prostate cancer cell aggressiveness by FTY720: validating Runx2 as a potential antimetastatic drug screening platform. Clin Cancer Res 2009; 15: 4322–4335.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This research was supported by a National Research Foundation of Korea (NRF) Grant funded by the Korea government (MEST; 2012-0000478) and by a grant from the Next-Generation BioGreen 21 Program (No. PJ0081952011), Rural Development Administration, Republic of Korea.

Author information

Authors and Affiliations

  1. Department of Urology, College of Medicine, Chungbuk National University, Cheongju, South Korea

    S J Yun, H-Y Yoon & W-J Kim

  2. Department of Biochemistry, College of Medicine, Chungbuk National University, Cheongju, South Korea

    S-C Bae

  3. Department of Pathology, College of Medicine, Chungbuk National University, Cheongju, South Korea

    O-J Lee

  4. Department of Biochemistry, Dongeui University College of Oriental Medicine, Busan, South Korea

    Y-H Choi

  5. Department of Food and Biotechnology, Chungju National University, Chungju, South Korea

    S-K Moon

  6. Section of Urologic Oncology, The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, New Brunswick, NJ, USA

    I Y Kim

Authors
  1. S J Yun
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H-Y Yoon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S-C Bae
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. O-J Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Y-H Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S-K Moon
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. I Y Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. W-J Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to W-J Kim.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yun, S., Yoon, HY., Bae, SC. et al. Transcriptional repression of RUNX2 is associated with aggressive clinicopathological outcomes, whereas nuclear location of the protein is related to metastasis in prostate cancer. Prostate Cancer Prostatic Dis 15, 369–373 (2012). https://doi.org/10.1038/pcan.2012.31

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/pcan.2012.31

Keywords

This article is cited by

Search

Advanced search

Quick links